Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-small-cell lung cancer: a systematic review and meta-analysis of …
W Deng, K Wang, Y Jiang, D Li, C Bao, J Luo, L Liu… - BMJ open, 2022 - bmjopen.bmj.com
Objectives Combination treatment with erlotinib plus bevacizumab has the potential to
become a standard treatment regimen for patients with epidermal growth factor receptor …
become a standard treatment regimen for patients with epidermal growth factor receptor …
[PDF][PDF] Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-small-cell lung cancer: a systematic review and meta-analysis of …
W Deng, K Wang, Y Jiang, D Li, C Bao, J Luo, L Liu… - scholar.archive.org
Objectives Combination treatment with erlotinib plus bevacizumab has the potential to
become a standard treatment regimen for patients with epidermal growth factor receptor …
become a standard treatment regimen for patients with epidermal growth factor receptor …
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-small-cell lung cancer: a systematic review and meta-analysis of …
W Deng, K Wang, Y Jiang, D Li, C Bao, J Luo, L Liu… - BMJ Open, 2022 - europepmc.org
Objectives Combination treatment with erlotinib plus bevacizumab has the potential to
become a standard treatment regimen for patients with epidermal growth factor receptor …
become a standard treatment regimen for patients with epidermal growth factor receptor …
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-small-cell lung cancer: a systematic review and meta-analysis of …
W Deng, K Wang, Y Jiang, D Li, C Bao, J Luo… - BMJ …, 2022 - search.proquest.com
Objectives Combination treatment with erlotinib plus bevacizumab has the potential to
become a standard treatment regimen for patients with epidermal growth factor receptor …
become a standard treatment regimen for patients with epidermal growth factor receptor …
[HTML][HTML] Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-small-cell lung cancer: a systematic review and meta-analysis …
W Deng, K Wang, Y Jiang, D Li, C Bao, J Luo, L Liu… - BMJ Open, 2022 - ncbi.nlm.nih.gov
Objectives Combination treatment with erlotinib plus bevacizumab has the potential to
become a standard treatment regimen for patients with epidermal growth factor receptor …
become a standard treatment regimen for patients with epidermal growth factor receptor …
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-small-cell lung cancer: a systematic review and meta-analysis of …
W Deng, K Wang, Y Jiang, D Li, C Bao, J Luo… - BMJ …, 2022 - pubmed.ncbi.nlm.nih.gov
Objectives Combination treatment with erlotinib plus bevacizumab has the potential to
become a standard treatment regimen for patients with epidermal growth factor receptor …
become a standard treatment regimen for patients with epidermal growth factor receptor …